Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Globus Medical, Inc. Class A Common Stock (NY:GMED)

75.50 +2.11 (+2.88%)
Official Closing Price Updated: 6:30 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Globus Medical, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
The Law Offices of Frank R. Cruz Continues Its Investigation of Globus Medical, Inc. (GMED) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Inspire Medical's Sleep Innovations Driving Big Gains
Inspire Medical, which makes innovative apnea relief devices, hit a key performance benchmark as its Relative Strength Rating jumped to 81. 
Via Investor's Business Daily
Lantheus Stock Doubled In A Year Amid Wide Use Of Its AI-Enabled Medical Devices
Lantheus Holdings sees its Relative Strength Rating reach the 80-plus level. 
Via Investor's Business Daily
Price Over Earnings Overview: Globus Medical
Via Benzinga
Why GLOBUS MEDICAL INC - A (NYSE:GMED) qualifies as a high growth stock.
Delving into GLOBUS MEDICAL INC - A (NYSE:GMED)'s high Growth Prospects. 
Via Chartmill
16 Analysts Have This To Say About Globus Medical
Via Benzinga
Should you consider GLOBUS MEDICAL INC - A (NYSE:GMED) for high growth investing?
Unlocking the high Growth Potential of GLOBUS MEDICAL INC - A (NYSE:GMED). 
Via Chartmill
Novocure Stock Earns 96 RS Rating
On Tuesday, Novocure stock got a positive adjustment to its Relative Strength (RS) Rating to 96, up from 73. 
Via Investor's Business Daily
Inari Medical Stock Gets RS Rating Upgrade
On Wednesday, Inari Medical stock received an upgrade to its Relative Strength (RS) Rating, from 65 to 72. 
Via Investor's Business Daily
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges. 
Via Benzinga
Evaluating Globus Medical: Insights From 11 Financial Analysts
Via Benzinga
Globus Medical Launches ExcelsiusHub™ Navigation System
From Globus Medical
Via GlobeNewswire
What 7 Analyst Ratings Have To Say About Globus Medical
Via Benzinga
The Analyst Verdict: Globus Medical In The Eyes Of 7 Experts
Via Benzinga
NYSE:GMED is showing good growth, while it is not too expensive.
In the world of growth stocks, NYSE:GMED shines as a value proposition. 
Via Chartmill
Despite its growth, NYSE:GMED remains within the realm of affordability.
GLOBUS MEDICAL INC - A (NYSE:GMED) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
CVS Health, Johnson Controls And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
Globus Medical (GMED) Q3 2024 Earnings Call Transcript
GMED earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Globus Medical Reports Third Quarter 2024 Results
From Globus Medical
Via GlobeNewswire
Looking Into Globus Medical's Recent Short Interest
Via Benzinga
A Glimpse Into The Expert Outlook On Globus Medical Through 8 Analysts
Via Benzinga
Globus Medical to Participate in Orthopedic Trauma Association Annual Meeting
From Globus Medical
Via GlobeNewswire
Globus Medical Schedules Third Quarter Earnings Release and Conference Call
From Globus Medical
Via GlobeNewswire
Globus Medical Launches the Next Wave of Orthopedic Trauma Solutions
From Globus Medical
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Bragar Eagel & Squire, P.C. Is Investigating MaxLinear, Customers Bancorp, Globus, and Metagenomi and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
While growth is established for NYSE:GMED, the stock's valuation remains reasonable.
While growth is established for NYSE:GMED, the stock's valuation remains reasonable. 
Via Chartmill
Bragar Eagel & Squire, P.C. Is Investigating MaxLinear, Customers Bancorp, Globus, and Domino’s and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Centuri, Medpace, Customers Bancorp, and Globus and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.